Superworth

Vir Biotechnology price to free cash flow VIR

Market value divided by free cash flow over the last twelve months, since 2022.

Today, Oct 23, 2026
n/m
not a meaningful number
Last meaningful
2.0×
Aug 2023
Peer median
31.1×

Vir Biotechnology's price to free cash flow is not a meaningful number today: free cash flow over the last twelve months was zero, negative or not reported.

It was last meaningful in Aug 2023, at 2.0×.

Price to free cash flow over time

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
20232.0×1.9×3.9×
20222.1×1.8×7.2×

Against its peers

Companies in Biotechnology nearest Vir Biotechnology's size, closest first, today.

CompanyPrice to free cash flow
VIRVir Biotechnologyn/m
VCELVericel35.3×
ADMAAdma Biologics20.5×
MGTXMeiraGTx84.5×
KRYSKrystal Biotech35.8×
RGENRepligen89.2×
TECHBIO-TECHNE43.2×
HALOHalozyme Therapeutics17.7×
NBIXNeurocrine Biosciences16.7×
PLXProtalix BioTherapeutics26.8×
EXELExelixis13.6×
Peer median31.1×

What the price to free cash flow tells you

Market value divided by free cash flow: the cash left after running the business and paying for equipment. Cash is harder to manage than accounting earnings, so many investors trust this more than PE.

Lumpy: a big year of building factories drops cash flow and inflates the ratio without the business getting worse.

More on Vir Biotechnology

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.